This week's roundup of Houston innovators includes Dorit Donoviel of TRISH, Nuri Firat Ince of UH, and Vanessa Wade of Connect the Dots. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space to engineering — recently making headlines in Houston innovation.


Dorit Donoviel, director of the Translational Research Institute for Space Health

Dorit Donoviel, director of the Translational Research Institute for Space Health

The new program will work with commercial spaceflight crews to bring back crucial research to one database. Photo via Libby Neder Photography

The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine announced a unique program that will work with commercial spaceflight providers and their passengers. The EXPAND — Enhancing eXploration Platforms and Analog Definition — Program will collect information and data from multiple space flights and organize it in one place. TRISH selected TrialX to build the centralized database.

"The space environment causes rapid body changes. This can help us understand how we humans react to and overcome stress. Ensuring that space explorers remain healthy pushes us to invent new approaches for early detection and prevention of medical conditions," says Dorit Donoviel, executive director at TRISH, in the release.

"Studying a broad range of people in space increases our knowledge of human biology. TRISH's EXPAND program will leverage opportunities with commercial spaceflight providers and their willing crew to open up new research horizons." Click here to read more.

Nuri Firat Ince, associate professor of biomedical engineering at UH

A medical device designed by a UH professor will close the loop with high frequency brain waves to prevent seizures from occurring. Photo via uh.edu

Nuri Firat Ince, an associate professor of biomedical engineering at UH, has received a federal grant aimed at helping stop epileptic seizures before they start. The BRAIN Initiative at the National Institute of Neurological Disorders and Stroke awarded the $3.7 million grant to go toward Ince's work to create a seizure-halting device based on his research.

According to UH, Ince has reduced by weeks the time it takes to locate the seizure onset zone (SOZ), the part of the brain that causes seizures in patients with epilepsy. He's done this by detecting high-frequency oscillations (HFO) forming "repetitive waveform patterns" that identify their location in the SOZ.

"If the outcomes of our research in acute settings become successful, we will execute a clinical trial and run our methods with the implanted … system in a chronic ambulatory setting," Ince says. Click here to read more.

Vanessa Wade, founder and owner of Connect the Dots

It's time for large corporations to step up to support small businesses founded by people of color. Photo courtesy

In her guest column for InnovationMap, Vanessa Wade addressed some of the challenges she faced founding a company as a person of color — specifically the lack of access to funding. In the article, she calls corporations to action to help business leaders like herself.

"The journey ahead can feel discouraging, but the good news is that now I have a much better idea of what it will take to build an equitable road back and get businesses like mine on even footing," she writes. Click here to read more. 

It's time for large corporations to step up to support small businesses founded by people of color. Photo via Getty Images

Houston expert: Corporations can help level the playing field for BIPOC-owned businesses

Guest column

There were times when I wasn't sure what to do next.

When I started Connect the Dots PR in 2012, I wrote out detailed business plans, saved startup dollars, and leaned heavily on people in the PR industry to guide me in terms of pricing and feedback. Of course, we had contingency plans for unexpected hardships, but you hope not to use them.

My contingency plans went out the window when we saw we were looking at more than a year of pandemic-related shutdowns and slowdowns. I didn't have time to wait it out or say let's see what happens. It was time to move strategically.

Like most businesses, we hit a snag. A big chunk of our client base was reeling with corporate layoffs, shutdowns and revamped budgets. We've held on, but at times, it was overwhelming. I remember when the pandemic initially shut everything down, my fear was what is going to happen to my business and those that depend on me, such as employees, vendors, clients and contractors? At the onset of the pandemic, an employee came to me and said if I needed to let them go they understood. It hurt to do so, but it was a mutual decision and he landed on his feet and relocated to another state.

For a business owner of color, the hurdles are higher. When building Connect the Dots PR, the most important driver was access to startup capital. But studies have shown that white entrepreneurs are able to contribute considerably more personal equity to their new businesses than entrepreneurs of color, because white American families have nearly 10 times as much wealth as Hispanic or Black American families.

While inequities existed before the pandemic, over the last year, they've gotten worse. Beyond the physical toll of COVID-19, which affected BIPOC (Black, Indigenous, People of Color) communities, which includes Hispanic and Asian American communities among others, more severely than white ones, BIPOC-owned businesses have had less of a safety net to fall back on, have been more likely to close, and have had a harder time getting Paycheck Protection Program loans. Studies last summer showed that the pandemic shuttered Black-owned businesses at more than double the rate of white-owned businesses. It all leads to the deeply unequal recovery that we're just now embarking upon.

The journey ahead can feel discouraging, but the good news is that now I have a much better idea of what it will take to build an equitable road back and get businesses like mine on even footing.

First and foremost, there needs to be an investment in people of color-owned businesses from the public, private and nonprofit sectors. Six months ago, I applied to the Comcast RISE program which, since late last year, has invested in 2,500 BIPOC-owned businesses nationwide with monetary grants, technology makeovers and marketing services. I received the Comcast RISE Investment Fund for Connect the Dots PR, which provided relief when it was most needed. With this grant, I have been able to focus on the business and invest in my brand.

We're not the only ones. Comcast RISE plans to name 13,000 recipients by 2022. Houston was also one of five cities selected to award a $10,000 grant to 100 local businesses from the Comcast RISE Investment Fund, which is the grant I received. We need similar commitments from other corporations to level the playing field for people of color business owners.

Federal, state and local recovery programs need to target minority entrepreneurs. Too many of the existing relief efforts have had limited application windows or been first-come-first-served, which disadvantages businesses that are already starting from behind. Local organizations like the Greater Houston Black Chamber of Commerce can be useful allies in reaching businesses owned by historically disadvantaged groups.

Finally, financial institutions need better guardrails to ensure that they don't discriminate against nonwhite business owners. When accessing startup capital, barriers still exist for minority entrepreneurs, and keeping checks and balances on those with the balance sheets is the only way to make sure all businesses are starting on equal footing.

That way, when the next crisis hits, you'll have fewer businesses starting from behind, and we'll all find our way to recovery much faster. For all of us, that's a business plan worth holding onto.

------

Vanessa Wade, is the founder and owner of Houston-based PR firm Connect the Dots.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.